DF/HCC Prostate SPORE
DF/HCC 前列腺孢子
基本信息
- 批准号:10628271
- 负责人:
- 金额:$ 24.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdministratorAdvocateAreaBostonCancer CenterClinical TrialsCollaborationsCommunicationCommunitiesConsentDana-Farber Cancer InstituteDedicationsDevelopmentEducationEducation and OutreachEnrollmentEnsureEnvironmentEthnic PopulationEvaluation ResearchEventFosteringFundingFutureGoalsGrantHuman ResourcesIndividualInfrastructureInstitutionLeadLeadershipLinkMalignant neoplasm of prostateMentorsMentorshipMissionModificationMonitorPatient EducationPatient advocacyPatientsPilot ProjectsProceduresProstateReportingReproduction sporesResearchResearch ActivityResearch PersonnelResource SharingResourcesScheduleScienceScientific Advances and AccomplishmentsTranslational ResearchUnderrepresented PopulationsUpdateWomanWorkanticancer researchcareer developmentdata sharingmeetingsmembermultidisciplinaryoutreachpatient populationprogramsracial populationsocial mediasuccesssymposiumtreatment and outcomeweb site
项目摘要
PROJECT SUMMARY – ADMINISTRATIVE CORE (CORE A)
The DF/HCC Prostate SPORE Administrative Core (Core A) is instrumental for the overall function and
success of the Prostate SPORE program. The Directors will work closely with Advisory Board Members,
Patient Advocates, and SPORE investigators to foster an environment that promotes collaboration and
transparency in research. Regular reviews and fiscal oversight by Core A will ensure that the program has the
resources it needs to be successful. Core A will also ensure that the SPORE integrates well with the broader
DF/HCC program and is capable of leveraging resources and institutional infrastructure to accelerate
translational prostate cancer research. The Administration Core’s Specific Aims are: 1) to provide resources
and fiscal oversight; 2) to monitor research progress and plan for the future; 3) to integrate the SPORE within
the Dana Farber/Harvard Cancer Center; 4) to foster collaborative research and dissemination of research
findings; and 5) to integrate a patient perspective throughout all research activities in the Prostate SPORE.
项目摘要 – 行政核心(核心 A)
DF/HCC 前列腺 SPORE 管理核心(核心 A)对于整体功能和
前列腺 SPORE 计划的成功,董事们将与顾问委员会成员密切合作,
患者权益倡导者和 SPORE 调查员营造一个促进合作和发展的环境
核心 A 的定期审查和财政监督将确保该计划具有
核心 A 还将确保 SPORE 与更广泛的领域良好整合。
DF/HCC 计划能够利用资源和机构基础设施来加速
转化性前列腺癌研究的具体目标是:1) 提供资源。
和财政监督;2) 监测研究进展并规划未来;3) 将 SPORE 纳入其中;
达纳法伯/哈佛大学癌症中心;4) 促进合作研究和研究传播
研究结果;5) 将患者的观点纳入前列腺 SPORE 的所有研究活动中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Himisha Beltran其他文献
Himisha Beltran的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Himisha Beltran', 18)}}的其他基金
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
“DNMT 和 TET1 重编程作为晚期前列腺癌的靶向耐药机制”
- 批准号:
10681632 - 财政年份:2023
- 资助金额:
$ 24.13万 - 项目类别:
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate Cancer
前列腺癌中 EZH2 和 PARP 抑制反应和耐药性的分子决定因素
- 批准号:
10628273 - 财政年份:2023
- 资助金额:
$ 24.13万 - 项目类别:
Molecular mechanisms underlying lineage plasticity in prostate cancer
前列腺癌谱系可塑性的分子机制
- 批准号:
10375455 - 财政年份:2020
- 资助金额:
$ 24.13万 - 项目类别:
Molecular mechanisms underlying lineage plasticity in prostate cancer
前列腺癌谱系可塑性的分子机制
- 批准号:
10596605 - 财政年份:2020
- 资助金额:
$ 24.13万 - 项目类别:
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer
项目1:早期检测转移性前列腺癌患者治疗耐药性的非侵入性临床检测
- 批准号:
10227729 - 财政年份:2017
- 资助金额:
$ 24.13万 - 项目类别:
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer
项目1:早期检测转移性前列腺癌患者治疗耐药性的非侵入性临床检测
- 批准号:
9763525 - 财政年份:
- 资助金额:
$ 24.13万 - 项目类别:
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer
项目1:早期检测转移性前列腺癌患者治疗耐药性的非侵入性临床检测
- 批准号:
9357038 - 财政年份:
- 资助金额:
$ 24.13万 - 项目类别:
Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer
项目1:早期检测转移性前列腺癌患者治疗耐药性的非侵入性临床检测
- 批准号:
9357038 - 财政年份:
- 资助金额:
$ 24.13万 - 项目类别:
相似海外基金
Examining the Impact of Medicaid's Prior Authorization Requirements for Tobacco Cessation Medications on Tobacco Cessation Medication Prescriptions
检查医疗补助计划对戒烟药物的事先授权要求对戒烟药物处方的影响
- 批准号:
10558258 - 财政年份:2023
- 资助金额:
$ 24.13万 - 项目类别:
SPORE University of Texas M. D. Anderson Cancer Center-Leukemia
SPORE 德克萨斯大学 MD 安德森癌症中心 - 白血病
- 批准号:
10911713 - 财政年份:2023
- 资助金额:
$ 24.13万 - 项目类别:
SAR 2023: From Mechanism to Patient-Centered Care: Research in Acupuncture and Traditional East Asian Medicine
SAR 2023:从机制到以患者为中心的护理:针灸和传统东亚医学研究
- 批准号:
10609124 - 财政年份:2023
- 资助金额:
$ 24.13万 - 项目类别: